Daily16h
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz20h
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
The American Journal of Managed Care7h
Studies Highlight Prognostic Value of Neutrophil-to-Lymphocyte Ratio in MPNs
Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...
ETF Daily News16h
Janney Montgomery Scott LLC Lowers Stake in Incyte Co. (NASDAQ:INCY)
The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and ...
The New York Times21h
New York Times - Top Stories
Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...